

**Serveur Académique Lausannois SERVAL [serval.unil.ch](http://serval.unil.ch)**

## **Author Manuscript**

**Faculty of Biology and Medicine Publication**

**This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.**

Published in final edited form as:

**Title:** ENaC activity in collecting ducts modulates NCC in cirrhotic mice.

**Authors:** Mordasini D, Loffing-Cueni D, Loffing J, Beatrice R, Maillard MP, Hummler E, Burnier M, Escher G, Vogt B

**Journal:** Pflugers Archiv : European journal of physiology

**Year:** 2015 Dec

**Volume:** 467

**Issue:** 12

**Pages:** 2529-39

**DOI:** 10.1007/s00424-015-1711-7

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

1 David Mordasini<sup>1</sup>, Dominique Loffing-Cueni<sup>4</sup>, Johannes Loffing<sup>4</sup>, Rohrbach Beatrice<sup>1</sup>, Marc P. Maillard<sup>2</sup>, Edith  
2 Hummler<sup>3</sup>, Michel Burnier<sup>2</sup>, Geneviève Escher<sup>1\*</sup> and Bruno Vogt<sup>1\*</sup>

3  
4 ENaC activity in collecting ducts modulates NCC in cirrhotic mice

5  
6  
7 <sup>1</sup>Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital,  
8 Department of Clinical Research, University of Bern, Switzerland; <sup>2</sup>Service of Nephrology and Hypertension,  
9 CHUV, Rue du Bugnon 17, CH-1005 Lausanne, Switzerland; <sup>3</sup>University of Lausanne, Department of  
10 Pharmacology and Toxicology, Rue du Bugnon 27, CH-1005 Lausanne; <sup>4</sup>University of Zurich, Institute of  
11 Anatomy, University of Zurich, Zurich, Switzerland

12 \*Contributed equally to the work

13  
14 **Correspondence:**

15 David Mordasini, PhD  
16 Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie, Inselspital  
17 CH-3010 Bern, Schweiz  
18 Phone: +41 31 632 9747  
19 Fax: +41 31 632 9444  
20 E-Mail: [david.mordasini@dkf.unibe.ch](mailto:david.mordasini@dkf.unibe.ch)

21  
22 **ABSTRACT:**

23 Cirrhosis is a frequent and severe disease, complicated by renal sodium retention leading to ascites and oedema.  
24 A better understanding of the complex mechanisms responsible for renal sodium handling could improve clinical  
25 management of sodium retention. Our aim was to determine the importance of the amiloride-sensitive epithelial  
26 sodium channel (ENaC) in collecting ducts in compensate and decompensate cirrhosis.

27 Bile duct ligation was performed in control mice (CTL) and collecting duct specific  $\alpha$ ENaC knock-out mice  
28 (KO), and ascites development, aldosterone plasma concentration, urinary sodium/potassium ratio and sodium  
29 transporter expression were compared.

30 Disruption of ENaC in cortical collecting ducts (CCDs) did not alter ascites development, urinary  
31 sodium/potassium ratio, plasma aldosterone concentrations, or Na,K-ATPase abundance in CCDs. Total  $\alpha$ ENaC  
32 abundance in whole kidney increased in cirrhotic mice of both genotypes and cleaved forms of  $\alpha$  and  $\gamma$  ENaC  
33 increased only in ascitic mice of both genotypes. The sodium chloride cotransporter (NCC) abundance was  
34 lower in non ascitic KO, compared to non ascitic CTL, and increased when ascites appeared.

35 In ascitic mice, the lack of  $\alpha$ ENaC in CDs induced an upregulation of total ENaC and NCC and correlated with  
36 the cleavage of ENaC subunits. This revealed compensatory mechanisms which could also take place when  
37 treating the patients with diuretics. These compensatory mechanisms should be considered for future  
38 development of therapeutic strategies.

39  
40 **KEYWORDS:** Ascites, aldosterone, cirrhosis, cortical collecting ducts, ENaC, NCC

## 42 INTRODUCTION

43 Cirrhosis is a frequent and severe disease, complicated by renal sodium retention leading to ascites and oedema.  
44 The development of the disease starts with damages to the liver architecture causing an increase of intrahepatic  
45 resistance and leading to portal hypertension. The latter is known to stimulate the production of nitric oxide,  
46 which in turn induces a peripheral arterial vasodilatation and causes intravascular volume insufficiency. This  
47 triggers mechanisms of sodium and water conservation through the renin-angiotensin-system, the sympathetic  
48 nervous system and the vasopressin pathway. It is hypothesized that an inadequate stimulation of these pathways  
49 leads to renal sodium retention which will favour ascites accumulation [13,25]. However, cellular and molecular  
50 mechanisms responsible for unbalanced renal sodium transport are incompletely understood.

51 We showed previously, that bile duct-ligated mice developed ascites concomitantly to Na,K-ATPase stimulation  
52 in cortical collecting ducts exclusively [1]. Underlining the role of the aldosterone sensitive distal nephron in  
53 ascites development, studies performed with rats showed an increased apical targeting of ENaC in ascitic  
54 animals [20,21]. In order to investigate the role of collecting ducts (CDs) in cirrhosis-induced sodium retention,  
55 we used a transgenic mouse model with a CD-specific inactivation of the amiloride sensitive sodium channel  
56 (ENaC) [29], which is crucial for regulated renal sodium reabsorption. Rubera *et al.* showed that mice with  
57 disruption of  $\alpha$ ENaC in CDs were still able to maintain sodium and potassium balance, even when challenged by  
58 salt restriction, water deprivation, or potassium loading [29]. Our hypothesis was that in pathological conditions,  
59 such as cirrhosis, CD function may become of importance.

60 The aim of the present study was to determine the importance of ENaC in CDs using the bile duct ligation-  
61 induced cirrhosis mouse model. We investigated ascites development, plasma aldosterone concentrations,  
62 urinary sodium and potassium excretion, as well as the expression of ENaC subunits, sodium chloride co-  
63 transporter (NCC) and Na,K-ATPase in control (CTL) and  $\alpha$ ENaC KO (KO) mice.

## 65 SUBJECTS AND METHODS

### 67 Animals

69 Animal studies were approved by the Veterinary Service of the Canton de Vaud, Switzerland. Experiments were  
70 performed on adult CTL (*Scnn1a*<sup>lox/lox</sup>) and  $\alpha$ ENaC KO (*Hoxb7::cre/scnn1a*<sup>lox/lox</sup>) mice.

### 72 Bile duct ligation

74 The bile duct ligation was performed under anaesthesia mediated by isoflurane inhalation (57 CTL and 53 KO).  
75 A ventral incision was made; ligatures were tightened around the bile duct and the segment in between excised.  
76 The same procedure was performed in SHAM-operated mice (12 CTL and 10 KO) except that no ligatures were  
77 tightened. After ligation, abdominal muscles were sutured and skin closed with *Michel's* suture clips. Mice were  
78 observed daily and received paracetamol (200 mg·kg<sup>-1</sup>·day<sup>-1</sup>) in drinking water for 2 days following surgery.

### 80 Ascites quantitation

81

82 Ascites development was monitored by body weight measurement. The mice with or without ascites were  
83 determined *a posteriori* at the time of sacrifice; mice with ascites at the time of sacrifice were considered as mice  
84 BDL+ even ascites was not present yet. The rate of ascites accumulation was estimated by the calculation of  
85 bodyweight difference between a measurement and the previous one.

86

87 Plasma aldosterone concentrations

88

89 Plasma aldosterone concentrations were measured by RIA (Coat-a-Count; Diagnostics Products Inc.).

90

91 Immunostaining

92

93 Kidneys of anesthetized mice were fixed for 5 minutes with 3% PFA in phosphate buffer by retrograde perfusion  
94 via the abdominal aorta [22]. Kidneys were cut in thin sections, frozen in liquid propane and stored at -80°C  
95 until further analysis. Immunohistochemistry was performed on 4 µm cryosections. Sections were blocked with  
96 10% normal goat serum and subsequently incubated over night at 4°C with the primary antibodies (N-ter αENaC  
97 1/5000 [32]); followed by a Cy3-conjugated donkey anti-rabbit IgG (Jackson Immuno Research Laboratories)  
98 diluted 1/1000. The sections were analysed by a fluorescence microscope (Leica). Pictures were taken with a  
99 CCD-camera and processed with Adobe Photoshop and Microsoft PowerPoint softwares.

100

101 Urine collection

102

103 Mice were installed into restraining tube, every 3 to 4 days from 8:00 am to 11:00 am, for urine collection.  
104 Urinary sodium and potassium were measured by flame photometry (IL943, Instrumentation Laboratory).

105

106 Microdissection of renal tubules

107

108 The left kidney was perfused with a liberase containing solution (liberase TM 33 µg/ml from Roche in  
109 DMEM/F-12, 1:1; Invitrogen). Pyramids cut along the corticomedullary axis were incubated at 30°C for 40 min  
110 in perfusion medium. Tubules were isolated in ice-cold DMEM/F-12 supplemented with 0.05% BSA without  
111 liberase. Tubules were transferred into 96 well plates and photographed. The total length of tubules was  
112 measured using Image J [31].

113

114 Na,K-ATPase Assay

115

116 Na,K-ATPase activity was determined as previously described [5]. Total ATPase activity was determined in a  
117 solution containing 50 mM NaCl, 5 mM KCl, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 100 mM Tris-HCl, 10 mM Na<sub>2</sub>ATP,  
118 and 8 nCi/µl of ATP [ $\gamma$ -<sup>32</sup>P] (10 Ci/mmol, 2 mCi/ml, Perkin Elmer: BLU002250UC) at pH 7.4. For Na<sup>+</sup>, K<sup>+</sup>-  
119 independent ATPase activity measurements, NaCl and KCl were omitted, Tris-HCl was 150 mM, and 2 mM  
120 ouabain was added. Na,K-ATPase activity was taken as the difference between total and Na<sup>+</sup>, K<sup>+</sup>-independent  
121 ATPase activities and expressed as the mean in pmole·mm<sup>-1</sup>·hour<sup>-1</sup> of n measurements.

122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161

## SDS-PAGE and Immunoblotting

Kidneys were homogenized using a Dounce tissue grinder and membrane proteins extracted in presence of protease and phosphatase inhibitors (No. 78440, Pierce) according to the manufacturer protocol (MEM Per Plus Kit No. 89842, Pierce). Protein concentration was quantified using the BCA protein assay kit (No. 23225, Pierce). Ten microgram were separated by SDS-PAGE, then transferred on nitrocellulose membrane and stained with Ponceau red before immunodetection. Nitrocellulose membranes were incubated with primary antibodies detecting,  $\alpha$ ENaC (1/10000) [32],  $\beta$ ENaC (1/10000) [33] and  $\gamma$ ENaC (1/10000) [33] and NCC (1/10000) [32]. Immunoblots were scanned using the Molecular Imager Chemidoc XRS+ (Biorad). Relative quantification was obtained by dividing the densitometric values of the proteins of interest by the densitometric values obtained with Ponceau red staining for the corresponding lane.

## Total RNA extraction and qPCR

Total RNA was extracted from kidneys with Trizol according manufacturer's protocol (Life Technologies). Reverse transcription was performed on 1  $\mu$ g of total RNA with the ImProm-II™ Reverse Transcription System (Promega). Relative abundances of transcripts were calculated after qPCR amplification. Primers and probes number - corresponding to the Universal ProbeLibrary (Roche) - targeting transcripts of interest, described in **table 1**, were designed using ProbeFinder software (Roche).

## Statistics

Results are expressed as means  $\pm$  SEM from several animals. To determine statistically significant differences, Student t-test or 1- or 2-way analysis of variance were used, followed by Bonferroni's tests for multiple comparisons.

## RESULTS

### Control and collecting duct alpha ENaC KO mice develop ascites

The presence of ascites was a prerequisite to identify cirrhotic mice with sodium retention. Ascites development was indirectly estimated by body weight measurement (**Fig. 1A and B**). Around ten days after BDL, 30% of CTL (17 out of 57) and 36% of KO (18 out of 53) of bile duct-ligated mice rapidly gained weight due to ascites accumulation (BDL+). Mice were sacrificed when ascites was observed for several consecutive days. The proportion of mice developing ascites and their survival rate after bile duct ligation were not affected by the genotype (**Fig. 1C**). Ascites accumulated at 1 ml per day and its volume reached about 10 ml at the time of sacrifice (**Fig. 1D**). Mice which did not gain weight (BDL-) over a period of 20 to 30 days after BDL were sacrificed and considered to be mice with compensated cirrhosis (BDL-).

162 Immunolocalization confirms  $\alpha$ ENaC disruption in CDs

163

164 Deletion of  $\alpha$ ENaC along collecting ducts (CDs) of  $\alpha$ ENaC KO mice was assessed by immunostaining (**Fig. 2**).  
165 In CTL mice,  $\alpha$ ENaC was seen in all principal cells of CDs, independent from the group (SHAM, BDL-, and  
166 BDL+). In KO mice,  $\alpha$ ENaC was absent from CD cells. A very few principal cells with remaining  $\alpha$ ENaC  
167 expression were seen in the initial cortical collecting duct.

168

169 Urinary sodium and potassium excretion are similar in CTL and  $\alpha$ ENaC KO mice

170

171 As expected in mice retaining sodium, 2-way analysis of variance with presence of ascites (BDL- vs BDL+) and  
172 genotype as a factor revealed a significant reduction of the urinary  $\text{Na}^+$ /Creatinine as well as  $\text{Na}^+$ / $\text{K}^+$  ratio in  
173 BDL+ ( $p = 0.0133$  and  $p = 0.0217$  respectively), which was not affected by the genotype (**Fig. 3A**).

174

175 Plasma aldosterone concentrations increase in CTL and  $\alpha$ ENaC KO mice with ascites

176

177 Plasma aldosterone concentrations increased independently of genotypes following bile duct ligation. A 2-way  
178 analysis of variance of aldosterone plasma concentrations between SHAM, BDL- and BDL+ revealed a  
179 significant increase in BDL+ mice (**Fig. 3B**).

180

181 ENaC is upregulated in cirrhotic CTL and KO mice

182

183 Immunoblots on membrane proteins extracted from kidney homogenates showed increased  $\alpha$ ENaC abundance in  
184 cirrhotic mice (BDL- or BDL+) (**Fig. 4A**). The cleaved form of  $\alpha$ ENaC appeared as doublets, as previously  
185 observed by others [6,10,11]. Statistical analysis of band density quantifications revealed (**Fig. 4B**) an  
186 upregulation of total  $\alpha$ ENaC (full and cleaved forms) in ascitic KO mice and interestingly a greater abundance of  
187  $\alpha$ ENaC in KO BDL+ vs CTL BDL+ mice. Analysis of the full form showed an increase in BDL- and BDL+  
188 mice, with no differences between genotypes (**Fig. 4C**). An increase of the  $\alpha$ ENaC cleaved form was observed in  
189 ascitic mice; however it was significant only in the KO BDL+ likely due to the variability observed in CTL  
190 BDL+ mice. The abundance of the cleaved form was higher in KO BDL+ versus CTL BDL+ ( $p < 0.01$ ) (**Fig.**  
191 **4D**). The abundance of transcript coding for ENaC (*scnn1a*) was affected in BDL+ mice independently of  
192 genotypes (**Fig. 4E**).

193 The expression of  $\beta$ ENaC subunit (**Fig. 5A**) was not altered in CTL BDL- and CTL BDL+ mice, but was  
194 increased in KO BDL- mice (**Fig. 5B**). The abundance of transcript coding for ENaC (*scnn1a*) was affected in  
195 BDL+ mice independently of genotypes (**Fig. 5C**).

196 Immunoblots showed a higher abundance of the  $\gamma$ ENaC cleaved form compared to its full form for two CTL  
197 BDL+ and KO BDL+ mice and the quasi absence of the  $\gamma$ ENaC cleaved form in BDL- (**Fig. 6A**). The full  
198  $\gamma$ ENaC is less abundant in BDL+ than in BDL+ in both genotypes (**Fig. 6C**) while  $\gamma$ ENaC cleaved form is more  
199 abundant in BDL+ than in BDL- mice (**Fig. 6D**). The abundance of transcript coding for ENaC (*scnn1a*) was  
200 affected in BDL+ mice independently of genotypes (**Fig. 6E**).

201

202 The absence of ENaC activity in collecting ducts does not influence Na,K-ATPase abundance

203

204 Previously used as a marker for sodium reabsorption along renal tubules [1], the Na,K-ATPase activity  
205 measurements performed in microdissected tubules at  $V_{max}$  reflects the abundance of Na,K-ATPase holoenzyme.  
206 In this study, the measurements did not reveal differences between groups (**Fig. 7**).

207

208 Sodium chloride cotransporter abundance differs between CTL and KO cirrhotic mice

209

210 Immunoblots on membrane proteins extracted from whole kidney showed reduced NCC abundance in BDL-  
211 mice (**Fig. 8A**). Statistical analysis of band density quantification showed a downregulation of NCC in cirrhotic  
212 CTL BDL+ and KO BDL- (**Fig. 8B**). Since samples from CTL and KO were loaded on different gels, and thus  
213 could not be compared, we did a second electrophoresis to investigate differences between CTL and KO samples  
214 in SHAM, BDL- and BDL+ (**Fig. 9A and B**). This revealed a lower NCC abundance in KO BDL- than in CTL  
215 BDL-, and a higher abundance in KO BDL+ than in CTL BDL+ mice. The abundance of its transcript was not  
216 altered (**Fig. 8C**).

217

218 DISCUSSION

219

220 To our knowledge, this is the first study investigating the mechanisms of sodium retention by bile duct ligation  
221 in genetically modified animals. It demonstrated in ascitic mice that the disruption of ENaC and thus a lack of its  
222 activity in CDs induced ENaC and NCC in upstream segments. These results on ENaC expression are in line  
223 with previous studies demonstrating the importance of ENaC in CNTs for the regulation of sodium reabsorption  
224 [9,12,27].

225 The absence of ENaC in CDs did not alter ascites formation. It developed in 30% of CTL and 36% of KO bile  
226 duct-ligated mice.

227 The immunohistochemical studies confirmed the disruption of ENaC in CDs of KO mice. Although a very few  
228 single cells in cortical collecting ducts escape the cre recombinase mediated inactivation of  $\alpha$ ENaC, as  
229 previously reported [29], we consider it highly unlikely that these few single CD-cells with persistent  $\alpha$ ENaC  
230 expression can account for the absence of differences between CTL and KO mice. It is likely that upstream  
231 segments contribute to sodium retention.

232 The urinary  $\text{Na}^+$ /Creatinine as well as  $\text{Na}^+/\text{K}^+$  ratios were reduced and plasma aldosterone concentrations  
233 increased in BDL+, as observed in humans [4].

234 Western blot analysis showed for both genotypes, an increase of  $\alpha$ ENaC abundance in BDL- and BDL+, but it  
235 also revealed that the cleavage of  $\alpha$  and  $\gamma$  subunits was significant only in BDL+ mice, which were retaining  
236 sodium. In kidneys,  $\alpha$ ENaC protein abundance has been shown to be regulated by aldosterone, while  $\beta$ ENaC and  
237  $\gamma$ ENaC not or only weakly [6,26]. Moreover, aldosterone stimulation or low salt diet was shown to induce an  
238 apical redistribution of  $\alpha$ ENaC,  $\beta$ ENaC and  $\gamma$ ENaC [8,10,23,24,26] and cleavage of  $\alpha$ ENaC and  $\gamma$ ENaC [6,26].  
239 Cleavage of ENaC by exogenous trypsin has been linked to an increase of channel activity [8,28]. Kim *et al.*  
240 observed, in ascitic rats, an increased apical targeting of  $\alpha\beta\gamma$ ENaC in DCTs, CNTs and CDs, and cleavage of  
241  $\gamma$ ENaC, without changes of  $\alpha\beta\gamma$ ENaC protein abundance [21,20]. Altogether these results showed that in ascitic

242 animals,  $\alpha$  and  $\gamma$  ENaC are cleaved, suggesting an increase in ENaC activity and thus demonstrate its importance  
243 for sodium retention. Interestingly, in our study, the  $\alpha$ ENaC cleaved form was more abundant in KO BDL+ than  
244 in CTL BDL+ mice, suggesting insufficient sodium reabsorption and a need to compensate.  
245 We did not observe increase in NCC abundance, although NCC is described as an aldosterone induced protein  
246 [19]. The slight decrease in NCC abundance observed in CTL cirrhotic mice was not significant in contrast to  
247 what was previously reported [7,14,34]. In BDL- mice NCC protein expression was lower than in CTL, whereas  
248 in BDL+ mice, in which sodium retention occurs it was higher in KO than CTL mice and probably reached the  
249 same level as in the SHAM operated mice as shown by the results in **fig. 8**. These results suggested  
250 compensation by NCC of an insufficient ENaC activity in CDs. The reduced abundance of NCC in non ascitic  
251 mice may reflect the aldosterone escape phenomenon, characterized by a downregulation of NCC in presence of  
252 high plasma aldosterone concentrations and high salt diet [30]. Conditions which are similar to those  
253 encountered by the CTL cirrhotic mice; their plasma aldosterone concentrations are high and their salt intake  
254 sufficient. The downregulation of NCC could also be due to an increase in plasma potassium concentration [3].  
255 However, this hypothesis is unlikely since several studies performed in rats reported normal plasma potassium  
256 values in cirrhotic animals [14,15,17,18].  
257 In contrast to Ackermann *et al.*, we did not observe any significant up-regulation of the Na,K-ATPase activity in  
258 isolated CCDs between SHAM-operated and cirrhotic mice [1]. This difference could be due to the mouse  
259 strains used. In the previous study, CD1 mice were used whereas in the actual one, we used 129/Sv x C57BL/6,  
260 since they are more prone to develop ascites [2]. Additionally mice were analysed at different time point.  
261 In summary, our study showed that in pathological conditions such as cirrhosis, the amount of sodium  
262 reabsorbed through ENaC in CDs is likely not negligible and if not sufficient, NCC upregulation may happen.  
263 The upregulation of NCC could explain the blunted natriuretic effect of the amiloride observed in cirrhotic rats  
264 treated with amiloride [16].  
265 The control of renal sodium retention and ascites development is not trivial in cirrhotic patients. A better  
266 understanding of the mechanisms responsible for renal sodium handling would improve its clinical management.  
267 This study illustrates the usability of gene-modified mouse models to dissect the complex mechanisms of sodium  
268 retention. It revealed compensation mechanisms which could take place when we downregulate artificially ion  
269 transporters, similarly as what is done with diuretics. In conclusion, to develop efficient therapeutic strategies,  
270 we have to understand pathways leading to sodium/potassium imbalance and to further consider compensatory  
271 mechanisms.

272

## 273 ACKNOWLEDGEMENTS

274

275 We thank Professors A Doucet and B Rossier for constructive comments, Dr. H Mistry, Dr. G Crambert and Dr.  
276 N Faller for their helpful reading of the manuscript and discussions, and A Tedjani and A Menoud for the  
277 technical assistance. We thank Dr. F Schütz (Training and Outreach, Bioinformatics Core Facility, University of  
278 Lausanne) for its assistance with statistical analysis.

279 **Financial support:** This study was supported by grants from the Swiss National Science Foundation:  
280 31003A\_120406 and 31003A\_135417 attributed to BV. The laboratory of JL is supported by SNF grant  
281 310030\_143929/1.

282

283 REFERENCES

284

- 285 1. Ackermann D, Mordasini D, Cheval L, Imbert-Teboul M, Vogt B, Doucet A (2007) Sodium retention  
286 and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid  
287 receptor? *Hepatology* 46:173-179. doi:10.1002/hep.21699
- 288 2. Alaish SM, Torres M, Ferlito M, Sun CC, De Maio A (2005) The severity of cholestatic injury is  
289 modulated by the genetic background. *Shock* 24:412-416. doi:00024382-200511000-00003  
290 [pii]
- 291 3. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ (2001) Human  
292 bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid  
293 receptor. *J Biol Chem* 276:28857-28865. doi:10.1074/jbc.M011610200  
294 M011610200 [pii]
- 295 4. Arroyo V, Bernardi M, Epstein M, Henriksen JH, Schrier RW, Rodes J (1988) Pathophysiology of  
296 ascites and functional renal failure in cirrhosis. *J Hepatol* 6:239-257
- 297 5. Doucet A, Katz AI, Morel F (1979) Determination of Na-K-ATPase activity in single segments of the  
298 mammalian nephron. *Am J Physiol* 237:F105-113
- 299 6. Ergonul Z, Frindt G, Palmer LG (2006) Regulation of maturation and processing of ENaC subunits in  
300 the rat kidney. *Am J Physiol Renal Physiol* 291:F683-693. doi:00422.2005 [pii]  
301 10.1152/ajprenal.00422.2005
- 302 7. Fernandez-Llama P, Jimenez W, Bosch-Marce M, Arroyo V, Nielsen S, Knepper MA (2000)  
303 Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. *Kidney*  
304 *Int* 58:216-228. doi:kid156 [pii]  
305 10.1046/j.1523-1755.2000.00156.x
- 306 8. Frindt G, Ergonul Z, Palmer LG (2008) Surface expression of epithelial Na channel protein in rat  
307 kidney. *J Gen Physiol* 131:617-627. doi:10.1085/jgp.200809989  
308 jgp.200809989 [pii]
- 309 9. Frindt G, Palmer LG (2004) Na channels in the rat connecting tubule. *Am J Physiol Renal Physiol*  
310 286:F669-674. doi:10.1152/ajprenal.00381.2003  
311 00381.2003 [pii]
- 312 10. Frindt G, Palmer LG (2009) Surface expression of sodium channels and transporters in rat kidney:  
313 effects of dietary sodium. *Am J Physiol Renal Physiol* 297:F1249-1255.  
314 doi:10.1152/ajprenal.00401.2009  
315 00401.2009 [pii]
- 316 11. Frindt G, Palmer LG (2012) Regulation of epithelial Na<sup>+</sup> channels by adrenal steroids:  
317 mineralocorticoid and glucocorticoid effects. *Am J Physiol Renal Physiol* 302:F20-26.  
318 doi:10.1152/ajprenal.00480.2011  
319 ajprenal.00480.2011 [pii]
- 320 12. Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V  
321 (2015) PPARgamma agonist-induced fluid retention depends on alphaENaC expression in  
322 connecting tubules. *Nephron* 129:68-74. doi:10.1159/000370254  
323 000370254 [pii]
- 324 13. Gines P, Cardenas A, Arroyo V, Rodes J (2004) Management of cirrhosis and ascites. *N Engl J Med*  
325 350:1646-1654. doi:10.1056/NEJMra035021  
326 350/16/1646 [pii]
- 327 14. Graebe M, Brond L, Christensen S, Nielsen S, Olsen NV, Jonassen TE (2004) Chronic nitric oxide  
328 synthase inhibition exacerbates renal dysfunction in cirrhotic rats. *Am J Physiol Renal Physiol*  
329 286:F288-297. doi:10.1152/ajprenal.00089.2003  
330 00089.2003 [pii]
- 331 15. Jonassen TE, Brond L, Torp M, Graebe M, Nielsen S, Skott O, Marcussen N, Christensen S (2003)  
332 Effects of renal denervation on tubular sodium handling in rats with CBL-induced liver  
333 cirrhosis. *Am J Physiol Renal Physiol* 284:F555-563. doi:10.1152/ajprenal.00258.2002

334 00258.2002 [pii]  
335 16. Jonassen TE, Heide AM, Janjua NR, Christensen S (2002) Collecting duct function in liver cirrhotic  
336 rats with early sodium retention. *Acta Physiol Scand* 175:237-244. doi:993 [pii]  
337 17. Jonassen TE, Marcussen N, Haugan K, Skyum H, Christensen S, Andreasen F, Petersen JS (1997)  
338 Functional and structural changes in the thick ascending limb of Henle's loop in rats with liver  
339 cirrhosis. *Am J Physiol* 273:R568-577  
340 18. Jonassen TE, Nielsen S, Christensen S, Petersen JS (1998) Decreased vasopressin-mediated renal  
341 water reabsorption in rats with compensated liver cirrhosis. *Am J Physiol* 275:F216-225  
342 19. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA (1998) The thiazide-sensitive  
343 Na-Cl cotransporter is an aldosterone-induced protein. *Proc Natl Acad Sci U S A* 95:14552-  
344 14557  
345 20. Kim SW, Wang W, Nielsen J, Praetorius J, Kwon TH, Knepper MA, Frokiaer J, Nielsen S (2004)  
346 Increased expression and apical targeting of renal ENaC subunits in puromycin  
347 aminonucleoside-induced nephrotic syndrome in rats. *Am J Physiol Renal Physiol* 286:F922-  
348 935. doi:10.1152/ajprenal.00277.2003  
349 00277.2003 [pii]  
350 21. Kim SW, Wang W, Sassen MC, Choi KC, Han JS, Knepper MA, Jonassen TE, Frokiaer J, Nielsen S  
351 (2006) Biphasic changes of epithelial sodium channel abundance and trafficking in common  
352 bile duct ligation-induced liver cirrhosis. *Kidney Int* 69:89-98. doi:5000018 [pii]  
353 10.1038/sj.ki.5000018  
354 22. Loffing J, Loffing-Cueni D, Valderrabano V, Klausli L, Hebert SC, Rossier BC, Hoenderop JG, Bindels  
355 RJ, Kaissling B (2001) Distribution of transcellular calcium and sodium transport pathways  
356 along mouse distal nephron. *Am J Physiol Renal Physiol* 281:F1021-1027  
357 23. Loffing J, Pietri L, Aregger F, Bloch-Faure M, Ziegler U, Meneton P, Rossier BC, Kaissling B (2000)  
358 Differential subcellular localization of ENaC subunits in mouse kidney in response to high-  
359 and low-Na diets. *Am J Physiol Renal Physiol* 279:F252-258  
360 24. Loffing J, Zecevic M, Feraille E, Kaissling B, Asher C, Rossier BC, Firestone GL, Pearce D, Verrey F  
361 (2001) Aldosterone induces rapid apical translocation of ENaC in early portion of renal  
362 collecting system: possible role of SGK. *Am J Physiol Renal Physiol* 280:F675-682  
363 25. Martin PY, Gines P, Schrier RW (1998) Nitric oxide as a mediator of hemodynamic abnormalities  
364 and sodium and water retention in cirrhosis. *N Engl J Med* 339:533-541.  
365 doi:10.1056/NEJM199808203390807  
366 26. Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA (1999) Aldosterone-mediated regulation  
367 of ENaC alpha, beta, and gamma subunit proteins in rat kidney. *J Clin Invest* 104:R19-23.  
368 doi:10.1172/JCI7840  
369 27. Meneton P, Loffing J, Warnock DG (2004) Sodium and potassium handling by the aldosterone-  
370 sensitive distal nephron: the pivotal role of the distal and connecting tubule. *Am J Physiol*  
371 *Renal Physiol* 287:F593-601. doi:10.1152/ajprenal.00454.2003  
372 287/4/F593 [pii]  
373 28. Nesterov V, Dahlmann A, Bertog M, Korbmacher C (2008) Trypsin can activate the epithelial  
374 sodium channel (ENaC) in microdissected mouse distal nephron. *Am J Physiol Renal Physiol*  
375 295:F1052-1062. doi:10.1152/ajprenal.00031.2008  
376 00031.2008 [pii]  
377 29. Rubera I, Loffing J, Palmer LG, Frindt G, Fowler-Jaeger N, Sauter D, Carroll T, McMahon A,  
378 Hummler E, Rossier BC (2003) Collecting duct-specific gene inactivation of alphaENaC in the  
379 mouse kidney does not impair sodium and potassium balance. *J Clin Invest* 112:554-565.  
380 doi:10.1172/JCI16956  
381 112/4/554 [pii]  
382 30. Sandberg MB, Maunsbach AB, McDonough AA (2006) Redistribution of distal tubule Na<sup>+</sup>-Cl<sup>-</sup>  
383 cotransporter (NCC) in response to a high-salt diet. *Am J Physiol Renal Physiol* 291:F503-508.  
384 doi:00482.2005 [pii]  
385 10.1152/ajprenal.00482.2005

- 386 31. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis.  
387 Nat Methods 9:671-675
- 388 32. Sorensen MV, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, Ziegler U,  
389 Odermatt A, Loffing-Cueni D, Loffing J (2013) Rapid dephosphorylation of the renal sodium  
390 chloride cotransporter in response to oral potassium intake in mice. *Kidney Int* 83:811-824.  
391 doi:10.1038/ki.2013.14  
392 ki201314 [pii]
- 393 33. Wagner CA, Loffing-Cueni D, Yan Q, Schulz N, Fakitsas P, Carrel M, Wang T, Verrey F, Geibel JP,  
394 Giebisch G, Hebert SC, Loffing J (2008) Mouse model of type II Bartter's syndrome. II. Altered  
395 expression of renal sodium- and water-transporting proteins. *Am J Physiol Renal Physiol*  
396 294:F1373-1380. doi:10.1152/ajprenal.00613.2007  
397 00613.2007 [pii]
- 398 34. Yu Z, Serra A, Sauter D, Loffing J, Ackermann D, Frey FJ, Frey BM, Vogt B (2005) Sodium retention  
399 in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter  
400 (NCC). *Nephrol Dial Transplant* 20:1833-1841. doi:gfh916 [pii]  
401 10.1093/ndt/gfh916  
402  
403  
404

405 FIGURES LEGENDS

406

407 **Fig. 1**

408 Evolution of body weight (mean  $\pm$  SEM) after bile duct ligation of CTL (A) or  $\alpha$ ENaC KO (B) mice without  
409 (BDL-) and with (BDL+) ascites. Fate of mice after bile duct ligation: a 2-sample test for equality of proportions  
410 showed no differences between genotypes regarding ascites development (C). Indirect quantification of ascites  
411 accumulation rate (mean  $\pm$  SEM) 6 CTL and 5 KO mice (D).

412

413 **Fig. 2**

414 Renal immunolocalization of  $\alpha$ ENaC for SHAM, BDL- and BDL+ mice. Collecting ducts (C), proximal tubules  
415 (P).

416

417 **Fig. 3**

418 Urinary  $\text{Na}^+$ ,  $\text{K}^+$  / Creatinine and  $\text{Na}^+/\text{K}^+$  ratio and plasma aldosterone concentrations. Urinary  $\text{Na}^+/\text{Creatinine}$  is  
419 reduced in BDL+ mice (Fig 3A). 2-way ANOVA, with presence of ascites and genotype as factors; the  
420 difference between BDL- and BDL+ is significant ( $p = 0.0217$ ); neither the genotype nor the interaction is  
421 significant. Urinary  $\text{K}^+/\text{Creatinine}$  is similar between BDL- and BDL+. Urinary  $\text{Na}^+/\text{K}^+$  ratio (mean  $\pm$  SEM) of  
422 CTL and KO mice: without ascites, more than 2 weeks after bile duct ligation (BDL-) and with ascites, more  
423 than 2 weeks after bile duct ligation (BDL+). 2-way ANOVA, with presence of ascites and genotype as factors;  
424 the difference between BDL- and BDL+ is significant ( $p = 0.0133$ ); neither the genotype nor the interaction is  
425 significant. Aldosterone plasma concentrations (mean  $\pm$  SEM) of CTL and KO mice: sham-operated (SHAM);  
426 without (BDL-) and with (BDL+) ascites (B). A Bonferroni's post test showed that the BDL+ groups (CTL or  
427 KO) are significantly different from their respective SHAM groups ( $p < 0.0001$  in both cases); the difference  
428 between SHAM and BDL- group is not significant.

429

430 **Fig. 4**

431  $\alpha$ ENaC abundance. Membrane protein extracts from whole kidneys from CTL (n=4) and KO (n=4) mice were  
432 loaded on a single 10% polyacrylamide gel (A) and quantified. 2-way ANOVA with health status (Healthy mice,  
433 SHAM, without ascites, BDL- and with ascites, BDL+) and genotype as factors, followed by Bonferroni's post-  
434 test revealed significant differences (\*) in the abundance of the total  $\alpha$ ENaC protein (B): KO SHAM vs KO  
435 BDL+,  $p < 0.0001$ ; KO BDL- vs KO BDL+,  $p = 0.0017$ ; CTL BDL+ vs KO BDL+  $p = 0.0096$ ; for the  
436 abundance of the full  $\alpha$ ENaC protein: CTL SHAM vs CTL BDL-,  $p = 0.0107$  (C); KO SHAM vs KO BDL-,  $p =$   
437  $0.0498$ ; KO SHAM vs KO BDL+,  $p = 0.0025$ ; and in the  $\alpha$ ENaC cleaved protein (D): KO SHAM vs KO BDL-,  
438  $p = 0.0005$ ; KO SHAM vs KO BDL+,  $p = 0.0014$ ; CTL BDL+ vs KO BDL+,  $p = 0.018$ . A 2-way ANOVA  
439 revealed a significant difference for *scnn1a* abundance between SHAM and BDL+ ( $p = 0.0133$ ), but neither the  
440 genotype nor the interaction were significant (E).

441

442 **Fig. 5**

443  $\beta$ ENaC abundance. Membrane protein extracts from whole kidneys from CTL (n=4) and KO (n=4) mice were  
444 loaded on a single 10% polyacrylamide gel (A) and quantified (B). 2-way ANOVA with health status (Healthy

445 mice, SHAM, without ascites, BDL- and with ascites, BDL+) and genotype as factors, followed by Bonferroni's  
446 post-test revealed significant differences (\*) in the abundance of the  $\beta$ ENaC protein (B): KO SHAM vs KO  
447 BDL-,  $p < 0.0003$ ; KO BDL- vs KO BDL+,  $p = 0.0001$ ; CTL BDL- vs KO BDL-  $p = 0.0375$  (B). A 2-way  
448 ANOVA revealed a significant difference for *scnn1b* abundance between SHAM and BDL+ ( $p = 0.0185$ ), but  
449 neither the genotype nor the interaction were significant (C).

450

451 **Fig. 6**

452  $\gamma$ ENaC abundance. Membrane protein extracts from whole kidneys CTL (n=4) of and KO (n=4) of mice were  
453 loaded on two different 4-20% polyacrylamide gels (A). Since samples from CTL and KO were not loaded on  
454 the same gel, only a 1-way ANOVA was possible: No differences were seen in the total  $\gamma$ ENaC protein (full and  
455 cleaved) (B); Significant differences were revealed for the abundance of the full  $\gamma$ ENaC protein: CTL BDL- vs  
456 CTL BDL+, adj.  $p = 0.0134$ ; KO BDL- vs KO BDL+, adj.  $p = 0.0243$  (C); and in the  $\gamma$ ENaC cleaved protein  
457 (D): CTL BDL- vs CTL BDL+, adj.  $p = 0.044$ ; KO BDL- vs KO BDL+, adj.  $p = 0.0098$ . A 2-way ANOVA  
458 revealed a significant difference for *scnn1a* abundance between SHAM and BDL+ ( $p = 0.0133$ ), but neither the  
459 genotype nor the interaction were significant (E).

460

461 **Fig. 7**

462 Na,K-ATPase abundance in cortical collecting ducts. Na,K-ATPase abundance was quantified by measuring the  
463 Na,K-ATPase activity at  $V_{max}$  in microdissected CCDs from CTL and collecting ducts specific  $\alpha$ ENaC KO mice  
464 for the 3 groups: SHAM-operated, without ascites (BDL-) and with (BDL+). Values represent the means  $\pm$  SEM  
465 from 3 to 7 mice. The number into the columns represents the n.

466

467 **Fig. 8**

468 NCC abundance: Comparison between SHAM, BDL- and BDL+. Membrane protein extracts from whole  
469 kidneys of CTL and KO were loaded on a 10% polyacrylamide gel (A) and quantified (B). Since samples from  
470 CTL and KO were not loaded on the same gel, only a 1-way ANOVA was possible: Significant differences were  
471 revealed for the abundance of NCC in the KO group: SHAM vs BDL-,  $p = 0.0287$  and BDL- vs BDL+,  $p =$   
472  $0.0075$ . No difference in the relative *sl12a3* (NCC) abundance (C).

473

474 **Fig. 9**

475 NCC abundance: Comparison between CTL and KO. Membrane protein extracts from whole kidneys SHAM,  
476 BDL- and BDL+ were loaded on a 10% polyacrylamide gel (A) and quantified (B). Significant differences were  
477 revealed for the abundance of NCC in cirrhotic mice, by Student t-test followed by Mann-Whitney post-test:  
478 CTL BDL- vs KO BDL-,  $p < 0.01$  and CTL BDL+ vs KO BDL+,  $p < 0.01$ .

FIGURE 1




FIGURE 2







FIGURE 3




# A FIGURE 4




## B



## E



## C



## D









FIGURE 5




# A FIGURE 6




## B Total $\gamma$ ENaC protein



## E scnn1g transcript



## C Full $\gamma$ ENaC protein



## D Cleaved $\gamma$ ENaC protein




FIGURE 7






FIGURE 8



**B** NCC protein



**C** slc12a3 transcript




FIGURE 9

